Repositioning of the global epicentre of non-optimal cholesterol

High blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health4,5. However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol—which is a marker of cardiovascular risk—changed from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95% credible interval 3.7 million–4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.</p

Repositioning of the global epicentre of non-optimal cholesterol

High blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health4,5. However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol�which is a marker of cardiovascular risk�changed from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95 credible interval 3.7 million�4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world. © 2020, The Author(s), under exclusive licence to Springer Nature Limited

Rising rural body-mass index is the main driver of the global obesity epidemic in adults

Body-mass index (BMI) has increased steadily in most countries in parallel with a rise in the proportion of the population who live in cities 1,2 . This has led to a widely reported view that urbanization is one of the most important drivers of the global rise in obesity 3�6 . Here we use 2,009 population-based studies, with measurements of height and weight in more than 112 million adults, to report national, regional and global trends in mean BMI segregated by place of residence (a rural or urban area) from 1985 to 2017. We show that, contrary to the dominant paradigm, more than 55 of the global rise in mean BMI from 1985 to 2017�and more than 80 in some low- and middle-income regions�was due to increases in BMI in rural areas. This large contribution stems from the fact that, with the exception of women in sub-Saharan Africa, BMI is increasing at the same rate or faster in rural areas than in cities in low- and middle-income regions. These trends have in turn resulted in a closing�and in some countries reversal�of the gap in BMI between urban and rural areas in low- and middle-income countries, especially for women. In high-income and industrialized countries, we noted a persistently higher rural BMI, especially for women. There is an urgent need for an integrated approach to rural nutrition that enhances financial and physical access to healthy foods, to avoid replacing the rural undernutrition disadvantage in poor countries with a more general malnutrition disadvantage that entails excessive consumption of low-quality calories. © 2019, The Author(s)

A new software for age estimation in adults by pulp/tooth ratio in canines using periapical X-rays: preliminary results.

The age estimation of adult individuals is an important problem in forensic human identification. This is usually performed by methods based on age-related changes of human skeleton. In the present paper, the pulp/tooth ratio in peri-apical X-rays of canine is used for age estimation purposes. An image segmentation method is proposed for the automatic computation of the above mentioned area, and its implementation by a Matlab code is used to obtain a practical study on 70 canine radiographies of distinct known aged individuals

Avaliação hematológica e bioquímica de equinos suplementados com óleo de arroz semirrefinado, rico em gamaorizanol Hematological and biochemical evaluation of horses supplemented with semi-refined rice oil enriched with gamma orizanol

Avaliou-se o efeito da suplementação com óleo de arroz sobre o peso e perfil hematológico de equinos submetidos a exercício físico moderado. Foram utilizados 14 equinos machos, com peso aproximado de 411kg, distribuídos entre o grupo tratado (GT; n=7), suplementado com óleo de arroz adicionado diariamente à dieta (0,5ml/kg/PV), e o grupo-controle (GC; n=7), tratado com óleo de soja (0,5ml/kg/PV). Foram feitas três avaliações: antes do início e aos 20 e 40 dias após o início do tratamento, as quais consistiram de determinação do peso, exame clínico e coleta de amostras de sangue dos animais, antes e após o exercício, para hematócrito, hemograma, dosagem de glicose, lactato e proteína total. Não houve diferença entre grupos e nem entre avaliações quanto às variáveis peso e proteína total. A glicose aumentou significativamente após o exercício na segunda coleta no GC e na terceira no GT. No GC, o lactato aumentou nas coletas após o exercício, enquanto no GT, os valores foram semelhantes antes e após. A suplementação com óleo de arroz na dieta foi determinante para impedir o aumento de lactato em equinos submetidos a exercício, o que pode ser relevante para aumentar o seu desempenho atlético.<br>The effect of the supplementation with rice oil was evaluated on the weight and hematologic profile of equines submitted moderate physical exercise. Fourteen male equines, averaging 411kg, were distributed into treated group (GT; n=7), supplemented daily with rice oil added to the diet (0.5ml/kg/BW); and control group (GC; n=7), treated with soybean oil (0.5ml/kg/BW). Three evaluations were made before the treatment, and 20 and 40 days after the beginning of the treatment, consisting of the determination of the weight, the clinical examination, and the collection of blood samples before and after the exercise for hematocrit, hemogram, glucose, lactate, and total protein determinations. There was no difference between the groups, neither between evaluations for weight nor total protein. The glucose increased significantly after the exercise in the second collection in the GC and in the third in the GT. The GC lactate increased significantly in the collections after exercise; while in the GT, the results were similar before and after treatments. The supplementation of the diet with rice oil was determinant to hinder the lactate increase in the animals submitted to exercise, what could be relevant to increase their athletic performance

Criteri di valutazione pneumologica per l'idoneità all'attività sportiva

Sono state pubblicate le nuove linee guida pneumologiche per la valutazione medico-sportiva. Gli autori dei vari capitoli sono eminenti specialisti della materia. Argomenti trattati: * LA VALUTAZIONE PNEUMOLOGICA * ANAFILASSI DA ESERCIZIO FISICO * ANOMALIE CONGENITE DELLE VIE AEREE * APNEA OSTRUTTIVA DA SONNO (OSAS) * ASMA BRONCHIALE * BRONCOPNEUMOPATIA CRONICA OSTRUTTIVA * EXERESI POLMONARE * FIBROSI CISTICA * INFEZIONI RESPIRATORIE ACUTE * INTERSTIZIOPATIE POLMONARI * IPOSSIEMIA INDOTTA DA ESERCIZIO FISICO * MAL DI MONTAGNA ED EDEMA POLMONARE D’ALTA QUOTA * MALFORMAZIONI TORACICHE * PLEURITI * PNEUMOTORACE * SARCOIDOSI * TRAUMATOLOGIA TORACICA * TROMBOEMBOLIA POLMONARE * TUBERCOLOSI POLMONARE * SINTESI IDONEATIVA PNUMOLOGICA * APPENDICE I: Questionario per OSAS * APPENDICE II: Test broncodinamici * APPENDICE III: procedure certificazione antidopin